1310 Chesapeake Terrace
410 articles with Accuray Inc.
Seven-year Data Shows Accuray TomoTherapy® System Provides Excellent Long-Term Control of Low-Risk Breast Cancer
Accuray Incorporated announced that data from a prospective, phase II trial of 338 women with low-risk breast cancer showed 98.8 percent had local disease control seven years after receiving once-daily accelerated partial breast irradiation delivered with the TomoTherapy® System.
Accuray Incorporated will report financial results for the second quarter of fiscal year 2021, ended December 31, 2020, after the market close on Wednesday January 27, 2021.
Accuray Incorporated announced its participation in the 39th J.P. Morgan Annual Healthcare Conference.
Accuray Incorporated reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Jim Dennison, the company's new Senior Vice President, Quality & Regulatory Affairs.
Accuray Appoints Renowned Medical Device Industry Executive Jim Dennison as Senior Vice President of Global Quality and Regulatory Affairs
Accuray Incorporated announced it has appointed Jim Dennison as its senior vice president of global quality and regulatory affairs, effective immediately.
Accuray Showcases Radiation Therapy Innovations Designed to Enable Better Outcomes with Less Damage, Less Time, and Less Cost, at ASTRO 2020
ASTRO Studies Focused on (Ultra) Hypofractionated Treatments Were Shared, Highlighting Experience of >1,400 Patients
Accuray Incorporated (NASDAQ: ARAY) announced today it has appointed Mike Leischer as its vice president and general manager, Americas (AMS) region, effective immediately. In this role, he will provide leadership of the AMS region commercial teams, driving development and implementation of a business strategy designed to achie
Accuray Incorporated will report financial results for the first quarter of fiscal year 2021, ended September 30, 2020, after the market close on Thursday, October 29, 2020.
Accuray Incorporated (NASDAQ: ARAY) announced today that the Company will host an Analyst & Investor Meeting on Monday, October 26 th , 2020 in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting. Presentations will begin at 1:00 pm ET ( 10:00 am PT ) and will conclude at 3:00 pm ET (12:0
Accuray Incorporated announced that Joshua H. Levine, president and chief executive officer and Shig Hamamatsu, chief financial officer will present at the fourth annual Lake Street Capital Markets Best Ideas Growth Conference on Thursday, September 17, 2020.
University Hospital Città della Salute e della Scienza, Turin, Italy is First in EIMEA to Treat Cancer Patients Using the Accuray Radixact® System with Synchrony® Technology
Renowned Hospital in Turin, Italy Uses Innovative Radiation Therapy Delivery System to Expand Options for Advanced Cancer Care to More Patients
Accuray Incorporated reported financial results for the fourth quarter and fiscal year ended June 30, 2020.
Accuray Incorporated announced the appointment of Anne B. Le Grand to the company's Board of Directors, effective as of July 16, 2020. In addition, she will serve on the Board's Nominating and Corporate Governance Committee. With Ms. Le Grand's appointment, the Accuray Board will consist of nine members.
Accuray Incorporated will report financial results for the fourth quarter and the 2020 fiscal year, ended June 30, 2020 after the market close on Thursday, August 13, 2020.
Geisinger Wyoming Valley Medical Center is First in the World to Treat Patients with the New System
Accuray Incorporated reported its financial results for the third quarter of fiscal 2020 ended March 31, 2020.
Accuray Incorporated reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Michael Hoge, the company's new Senior Vice President, Global Operations.
Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife® M6™ System in Missouri at their state-of-the-art David C. Pratt Cancer Center.
Studies Support Use of the Accuray TomoTherapy® System for Advanced Rectal Cancer to Improve Treatment Efficacy and Reduce Side Effects
Accuray Incorporated (NASDAQ: ARAY) announced today that two new studies demonstrate the benefits of the TomoTherapy® System in the treatment of advanced rectal cancer.
Accuray Incorporated, announced that Joshua H. Levine, president and chief executive officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 10:00 a.m. PT.